An observational study in Chronic Obstructive Pulmonary Disease (COPD) and Cardiovascular Diseases (CVD), sponsored by Hellenic Thoracic Society. Recruiting at 2 sites in Greece. Open to participants aged 35 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-09-16.
Sponsored by Hellenic Thoracic Society · Observational
COPD is one of the most common respiratory diseases in Greece, and maybe more than half a million Greek citizens suffer both from COPD and CVD, however their characteristics and management remain unknown. HELICOPD is a national, multicenter, prospective, non-interventional study designed to contribute to better understanding and depicting the demographic and clinical characteristics of this population, the COPD- and CVD-related adverse events in a two-years period, their quality of life and the healthcare resources use. The study is initiated and coordinated by the Hellenic Thoracic Society.
4,131 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 697 are open to participants now.
This study's planned enrollment of 900 is above the median of 180 across 1,066 observational studies indexed under Pulmonary Disease, Chronic Obstructive.
Browse Pulmonary Disease, Chronic Obstructive studies →This is the only study on the registry with Hellenic Thoracic Society as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Patients with COPD and cardiovascular comorbidities in Greece
Inclusion criteria
Patients should cumulatively meet the following three (3) criteria to be enrolled in the study:
Patients:
Number of moderate or severe COPD exacerbations
Moderate COPD exacerbation: typically requires outpatient management, it is characterized by an increased need for medication, specifically the use of systemic corticosteroids and/or antibiotics. Severe COPD exacerbation: indicated by an acute worsening of symptoms that requires hospitalization.
Time frame: Up to 24 months
Number of cardiovascular complications/outcomes
Cardiovascular complications/outcomes, including a) acute coronary syndrome, b) ischemic stroke, c) pulmonary embolism, d) reperfusion, e) worsening of heart failure that required a visit to the Emergency Department (ED) or hospitalization (short or longer), f) other hospitalization in a cardiology clinic (causes other than acute coronary syndrome, reperfusion, and heart failure), g) death related to cardiovascular disease.
Time frame: Up to 24 months
Unscheduled hospital admission due to COPD
Time frame: Up to 24 months
Unscheduled hospital admission due to any other reason
Time frame: Up to 24 months
Death (due to any cause)
Time frame: Up to 24 months
Healthcare resource utilization related costs
Time frame: Up to 24 months
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive→